Compare · APLS vs LLY
APLS vs LLY
Side-by-side comparison of Apellis Pharmaceuticals Inc. (APLS) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLS and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 221.1x APLS ($5.25B).
- LLY has hit the wire 16 times in the past 4 weeks while APLS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Apellis Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- $41.05-0.05%
- $1233.40-1.12%
- Market cap
- $5.25B
- $1.16T
- 1M return
- -
- +3.00%
- 1Y return
- -
- +67.64%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 0
- 16
- Recent ratings
- 25
- 25
Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest APLS
- Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.
- SEC Form 15-12G filed by Apellis Pharmaceuticals Inc.
- Director Dunlop A. Sinclair returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
- VP/Chief Accounting Officer Chopas James George was granted 38,244 shares and returned 76,650 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Director Dolsten Mikael returned 14,312 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Research and Development Meltzer Leslie returned 174,854 shares to the company and was granted 67,830 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Director Fonteyne Paul R. returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Financial Officer Sullivan Timothy Eugene was granted 159,080 shares and returned 270,413 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Machiels Alec returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Scientific Officer Deschatelets Pascal was granted 90,040 shares and returned 135,445 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation
Latest LLY
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- SVP, Finance, & CAO Zakrowski Donald A sold $2,370,020 worth of shares (2,000 units at $1,185.01) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 1,526 units (SEC Form 4)